{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:18:35Z","timestamp":1790745515984,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T00:00:00Z","timestamp":1478476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T00:00:00Z","timestamp":1478476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent drug discovery and development efforts have created a large arsenal of targeted and chemotherapeutic drugs for precision medicine. However, drug resistance remains a major challenge as minor pre-existing resistant subpopulations are often found to be enriched at relapse. Current drug design has been heavily focused on initial efficacy, and we do not fully understand the effects of drug selective pressure on long-term drug resistance potential. Using a minimal two-population model, taking into account subpopulation proportions and growth\/kill rates, we modeled long-term drug treatment and performed parameter sweeps to analyze the effects of each parameter on therapeutic efficacy. We found that drugs with the same overall initial kill may exert differential selective pressures, affecting long-term therapeutic outcome. We validated our conclusions experimentally using a preclinical model of Burkitt\u2019s lymphoma. Furthermore, we highlighted an intrinsic tradeoff between drug-imposed overall selective pressure and rate of adaptation. A principled approach in understanding the effects of distinct drug selective pressures on short-term and long-term tumor response enables better design of therapeutics that ultimately minimize relapse.<\/jats:p>","DOI":"10.1038\/srep36198","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T10:08:26Z","timestamp":1478513306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations"],"prefix":"10.1038","volume":"6","author":[{"given":"Daphne","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Dalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Hemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Lauffenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"BFsrep36198_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med"},{"key":"BFsrep36198_CR2","first-page":"105","volume":"1805","author":"A Marusyk","year":"2010","unstructured":"Marusyk, A. & Polyak, K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105\u2013117 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFsrep36198_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510 (2012).","journal-title":"Nature"},{"key":"BFsrep36198_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532\u2013536 (2012).","journal-title":"Nature"},{"key":"BFsrep36198_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nm.3841","volume":"21","author":"HC Bhang","year":"2015","unstructured":"Bhang, H. C. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440\u2013448 (2015).","journal-title":"Nat. Med"},{"key":"BFsrep36198_CR6","doi-asserted-by":"crossref","unstructured":"Leder, K. et al. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One 6 (2011).","DOI":"10.1371\/journal.pone.0027682"},{"key":"BFsrep36198_CR7","doi-asserted-by":"publisher","first-page":"13906","DOI":"10.1073\/pnas.1409362111","volume":"111","author":"NL Komarova","year":"2014","unstructured":"Komarova, N. L., Burger, J. A. & Wodarz, D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc. Natl. Acad. Sci. USA 111, 13906\u201313911 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR8","doi-asserted-by":"publisher","first-page":"15964","DOI":"10.1073\/pnas.1412075111","volume":"111","author":"I Bozic","year":"2014","unstructured":"Bozic, I. & Nowak, M. A. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl. Acad. Sci. USA 111, 15964\u201315968 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR9","doi-asserted-by":"crossref","unstructured":"Pena-Miller, R. et al. When the Most Potent Combination of Antibiotics Selects for the Greatest Bacterial Load: The Smile-Frown Transition. PLoS Biol. 11 (2013).","DOI":"10.1371\/journal.pbio.1001540"},{"key":"BFsrep36198_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jtbi.2009.11.022","volume":"263","author":"J Foo","year":"2010","unstructured":"Foo, J. & Michor, F. Evolution of resistance to anti-cancer therapy during general dosing schedules. J. Theor. Biol. 263, 179\u2013188 (2010).","journal-title":"J. Theor. Biol."},{"key":"BFsrep36198_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.trecan.2015.11.003","volume":"2","author":"KA Lipinski","year":"2016","unstructured":"Lipinski, K. A. et al. Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. Trends in Cancer 2, 49\u201363 (2016).","journal-title":"Trends in Cancer"},{"key":"BFsrep36198_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.trecan.2016.02.001","volume":"2","author":"B Zhao","year":"2016","unstructured":"Zhao, B., Hemann, M. T. & Lauffenburger, D. A. Modeling tumor clonal evolution for drug combinations design. Trends in Cancer 2, 144\u2013158 (2016).","journal-title":"Trends in Cancer"},{"key":"BFsrep36198_CR13","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1088\/1478-3975\/8\/1\/015002","volume":"8","author":"J Foo","year":"2011","unstructured":"Foo, J., Leder, K. & Michor, F. Stochastic dynamics of cancer initiation. Phys. Biol. 8, 15002 (2011).","journal-title":"Phys. Biol."},{"key":"BFsrep36198_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtbi.2004.09.001","volume":"233","author":"Y Iwasa","year":"2005","unstructured":"Iwasa, Y., Michor, F., Komarova, N. L. & Nowak, M. A. Population genetics of tumor suppressor genes. J. Theor. Biol. 233, 15\u201323 (2005).","journal-title":"J. Theor. Biol."},{"key":"BFsrep36198_CR15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1534\/genetics.166.3.1571","volume":"166","author":"Y Iwasa","year":"2004","unstructured":"Iwasa, Y., Michor, F. & Nowak, M. A. Stochastic Tunnels in Evolutionary Dynamics. Genetics 166, 1571\u20131579 (2004).","journal-title":"Genetics"},{"key":"BFsrep36198_CR16","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1371\/journal.pcbi.0030225","volume":"3","author":"N Beerenwinkel","year":"2007","unstructured":"Beerenwinkel, N. et al. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 3, 2239\u20132246 (2007).","journal-title":"PLoS Comput. Biol"},{"key":"BFsrep36198_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/eva.12024","volume":"6","author":"RS Datta","year":"2013","unstructured":"Datta, R. S., Gutteridge, A., Swanton, C., Maley, C. C. & Graham, T. A. Modelling the evolution of genetic instability during tumour progression. Evol. Appl. 6, 20\u201333 (2013).","journal-title":"Evol. Appl"},{"key":"BFsrep36198_CR18","doi-asserted-by":"publisher","first-page":"18135","DOI":"10.1073\/pnas.0705778104","volume":"104","author":"S-C Park","year":"2007","unstructured":"Park, S.-C. & Krug, J. Clonal interference in large populations. Proc. Natl. Acad. Sci. USA 104, 18135\u201318140 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR19","doi-asserted-by":"publisher","first-page":"18545","DOI":"10.1073\/pnas.1010978107","volume":"107","author":"I Bozic","year":"2010","unstructured":"Bozic, I. et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl. Acad. Sci. USA 107, 18545\u201318550 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/eva.12020","volume":"6","author":"JG Reiter","year":"2013","unstructured":"Reiter, J. G., Bozic, I., Allen, B., Chatterjee, K. & Nowak, M. A. The effect of one additional driver mutation on tumor progression. Evol. Appl. 6, 34\u201345 (2013).","journal-title":"Evol. Appl"},{"key":"BFsrep36198_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jtbi.2012.08.025","volume":"314","author":"K Danesh","year":"2012","unstructured":"Danesh, K., Durrett, R., Havrilesky, L. J. & Myers, E. A branching process model of ovarian cancer. J. Theor. Biol. 314, 10\u201315 (2012).","journal-title":"J. Theor. Biol."},{"key":"BFsrep36198_CR22","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1073\/pnas.1213968110","volume":"110","author":"CD McFarland","year":"2013","unstructured":"McFarland, C. D., Korolev, K. S., Kryukov, G. V., Sunyaev, S. R. & Mirny, L. A. Impact of deleterious passenger mutations on cancer progression. Proc. Natl. Acad. Sci. USA 110, 2910\u20132915 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR23","doi-asserted-by":"publisher","first-page":"15138","DOI":"10.1073\/pnas.1404341111","volume":"111","author":"CD McFarland","year":"2014","unstructured":"McFarland, C. D., Mirny, L. a. & Korolev, K. S. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc. Natl. Acad. Sci. USA 111, 15138\u201315143 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR24","doi-asserted-by":"crossref","unstructured":"Iwasa, Y. & Michor, F. Evolutionary dynamics of intratumor heterogeneity. PLoS One 6 (2011).","DOI":"10.1371\/journal.pone.0017866"},{"key":"BFsrep36198_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1534\/genetics.110.125724","volume":"188","author":"R Durrett","year":"2011","unstructured":"Durrett, R., Foo, J., Leder, K., Mayberry, J. & Michor, F. Intratumor heterogeneity in evolutionary models of tumor progression. Genetics 188, 461\u2013477 (2011).","journal-title":"Genetics"},{"key":"BFsrep36198_CR26","doi-asserted-by":"crossref","unstructured":"Antal, T. & Krapivsky, P. L. Exact solution of a two-type branching process: Models of tumor progression. J. Stat. Phys. P08018, doi: 10.1088\/1742-5468\/2011\/08\/P08018 (2011).","DOI":"10.1088\/1742-5468\/2011\/08\/P08018"},{"key":"BFsrep36198_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0022-5193(02)93112-7","volume":"219","author":"KM Page","year":"2002","unstructured":"Page, K. M. & Nowak, M. A. Unifying evolutionary dynamics. J. Theor. Biol. 219, 93\u201398 (2002).","journal-title":"J. Theor. Biol."},{"key":"BFsrep36198_CR28","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor, F. et al. Dynamics of chronic myeloid leukaemia. Nature 435, 1267\u20131270 (2005).","journal-title":"Nature"},{"key":"BFsrep36198_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2012.04.006","volume":"18","author":"I Bozic","year":"2012","unstructured":"Bozic, I., Allen, B. & Nowak, M. A. Dynamics of targeted cancer therapy. Trends in Molecular Medicine 18, 311\u2013316 (2012).","journal-title":"Trends in Molecular Medicine"},{"key":"BFsrep36198_CR30","doi-asserted-by":"crossref","unstructured":"Bozic, I. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013 (2013).","DOI":"10.7554\/eLife.00747.016"},{"key":"BFsrep36198_CR31","doi-asserted-by":"crossref","unstructured":"Shi, J., Alagoz, O., Erenay, F. S. & Su, Q. A survey of optimization models on cancer chemotherapy treatment planning. Annals of Operations Research 1\u201326, doi: 10.1007\/s10479-011-0869-4 (2011).","DOI":"10.1007\/s10479-011-0869-4"},{"key":"BFsrep36198_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1021\/ci700452r","volume":"48","author":"ML Radhakrishnan","year":"2008","unstructured":"Radhakrishnan, M. L. & Tidor, B. Optimal drug cocktail design: Methods for targeting molecular ensembles and insights from theoretical model systems. J. Chem. Inf. Model. 48, 1055\u20131073 (2008).","journal-title":"J. Chem. Inf. Model."},{"key":"BFsrep36198_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1158\/2159-8290.CD-13-0465","volume":"4","author":"B Zhao","year":"2014","unstructured":"Zhao, B., Pritchard, J. R., Lauffenburger, D. A. & Hemann, M. T. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 4, 166\u2013174 (2014).","journal-title":"Cancer Discov"},{"key":"BFsrep36198_CR34","doi-asserted-by":"publisher","first-page":"14586","DOI":"10.1073\/pnas.1203559109","volume":"109","author":"RA Beckman","year":"2012","unstructured":"Beckman, R. A., Schemmann, G. S. & Yeang, C.-H. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc. Natl. Acad. Sci. USA 109, 14586\u201314591 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR35","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894\u20134903 (2009).","journal-title":"Cancer Res"},{"key":"BFsrep36198_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cell.2016.01.045","volume":"165","author":"B Zhao","year":"2016","unstructured":"Zhao, B. et al. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell 165, 234\u2013246 (2016).","journal-title":"Cell"},{"key":"BFsrep36198_CR37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533\u2013538 (1985).","journal-title":"Nature"},{"key":"BFsrep36198_CR38","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1101\/gad.13.20.2670","volume":"13","author":"CA Schmitt","year":"1999","unstructured":"Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a\/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670\u20132677 (1999).","journal-title":"Genes Dev"},{"key":"BFsrep36198_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nchembio.503","volume":"7","author":"H Jiang","year":"2011","unstructured":"Jiang, H., Pritchard, J. R., Williams, R. T., Lauffenburger, D. A. & Hemann, M. T. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 7, 92\u2013100 (2011).","journal-title":"Nat Chem Biol"},{"key":"BFsrep36198_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","volume":"108","author":"R Fisher","year":"2013","unstructured":"Fisher, R., Pusztai, L. & Swanton, C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 108, 479\u2013485 (2013).","journal-title":"Br. J. Cancer"},{"key":"BFsrep36198_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/leu.2013.248","volume":"28","author":"Da Landau","year":"2014","unstructured":"Landau, D. a., Carter, S. L., Getz, G. & Wu, C. J. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 28, 34\u201343 (2014).","journal-title":"Leukemia"},{"key":"BFsrep36198_CR42","doi-asserted-by":"publisher","first-page":"13977","DOI":"10.1073\/pnas.0805965105","volume":"105","author":"M Hegreness","year":"2008","unstructured":"Hegreness, M., Shoresh, N., Damian, D., Hartl, D. & Kishony, R. Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. USA 105, 13977\u201313981 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36198_CR43","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/ng1651","volume":"37","author":"RA Dickins","year":"2005","unstructured":"Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289\u20131295 (2005).","journal-title":"Nat. Genet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36198","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:05:32Z","timestamp":1672877132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,7]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,21]]}},"alternative-id":["BFsrep36198"],"URL":"https:\/\/doi.org\/10.1038\/srep36198","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,7]]},"assertion":[{"value":"30 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.L. is a consultant\/advisory board member of Merrimack Pharmaceuticals, Genentech, and Complete Genomics. Remaining authors declare no potential conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36198"}}